3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Colorectal Neoplasms
45
Stomach Neoplasms
23
Pancreatic Neoplasms
22
Rectal Neoplasms
16
Esophageal Neoplasms
14
Adenocarcinoma Of Esophagus
14
Colonic Neoplasms
13
Neoplasms
11
Carcinoma, Non-Small-Cell Lung
11
Neoplasm Metastasis
10
Urinary Bladder Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
8
Esophageal Squamous Cell Carcinoma
7
Adenocarcinoma
7
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Ovarian Neoplasms
5
Cholangiocarcinoma
5
Lung Neoplasms
4
Endometrial Neoplasms
4
Carcinoma, Hepatocellular
4
Carcinoma
4
Head and Neck Neoplasms
3
Gastrointestinal Neoplasms
3
Breast Neoplasms
3
Biliary Tract Neoplasms
3
Advanced Solid Tumors
3
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Oropharyngeal Neoplasms
2
Melanoma
2
Interventions
darolutamide
2
pembrolizumab
1
olaparib
1
gedatolisib
1
enfortumab vedotin
1
Radiation Dose Hypofractionation
1
Pluvicto
1
Mitomycin
1
Gemcitabine
1
Fluorouracil
1
Cisplatin
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Male Urogenital Diseases
×
Fluorouracil
×
90 days
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled